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Reviews

Telomere, telomerase and digestive cancer
Javed Yakoob, HU Guo-Ling, FAN Xue-Gong and ZHANG Zheng
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Recent advances suggest that telomerase is
associated with cellular immortality which is a
hallmark of cancer.
TELOMERES

Human telomeres contain an array of tandem DNA
repeats. We share the telomeric sequence
(TTAGGG)n with all other vertebrates. Human
chromosomes end in several kilobases of telomeric
repeat DNA. These are oriented so that the guanine
(G)-rich strand runs out to the 3’ end of the
chromosome. Despite their monotonous sequence,
telomeres fulfil important functions. First, they
hide natural chromosome end from factors acting on
DNA termini unlike broken chromosome ends which
either get degraded or fuse to other DNA.
Telomeres are resistant to exonucleases and ligases.
They also escape detection by the DNA damage
checkpoints. The termini of natural chromosome
ends are probably concealed by a complex of
specialized proteins that bind telomeric DNA.
Telomere length is maintained by a balance between
the telomeres-lengthening process ( e.g.,
telomerase)[1] and the telomeres-shortening process
(end replication). The inability of the DNA to
completely replicate chromosome termini
(telomeres) leads to the progressive shortening of
chromosomes upon continuous cell division. The
shortening can ultimately lead to loss of telomeric
function and chromosomal destabilization. A DNA
polymerase called telomerase is required to
overcome the end replication.
TELOMERASE

Human telomerase is a ribonucleoprotein (RNP)
composed of an essential RNA and a few proteins.
It synthesizes the G-rich tandem repeats that
comprise telomeres [(TTAGGG)150-2000 in humans]
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using a template on the RNA that is complementary
to the telomeric repeat. By adding hexameric
(TTAGGG) repeats to the telomeric ends of the
chromosomes, the continued erosion of telomeres is
compensated. The enzyme is expressed in embryonic
cell and in adult male germ line cells[2], but is
undetectable in normal somatic cells except for
proliferative cells of renewable tissues (e.g.
haemopoetic stem cells and activated lymphocytes,
basal cells of the epidermis and intestinal crypt
cells). In normal somatic cells, progressive
shortening of telomere leads to a limited replicative
capacity. Recently more direct evidence has been
found in the role of telomere short ening in aging[3].
TELOMERIC PROTEINS

Telomeres are essential for the maintenance of
chromosomes. Another group of important
regulators for telomere function is the telomere
binding proteins[4]. They were originally described
as proteins, binding specifically to telomere DNA
(for example, to the hexameric repeat). The RAP 1
protein in budding yeasts and the TRF1 protein in
mammalian cells are examples of this class of
proteins[5]. Another type of proteins interacts with
the telomere DNA-binding protein/proteininteractions and comprises a large functional
chromosome domain called the “telosome” [6].
Examples are the SIR 3/SIR 4 proteins and the RIF
1 protein in saccharomyces cerevisiae[6]. These
proteins associate with the RAP 1 telomere DNAbinding protein and function to establish telomere
silencing effect and regulate telomere length
respectively. Some of these proteins negatively
regulate telomere length, probably by inhibiting
telome rase activity[7]. Therefore, the length and
function of telomere are not determined simply by
the balance between the total number of cell
divisions and telomerase activity.
TELOMERASE IN MALIGNANCY

While all of the steps leading to cancer are still
unknown, progression to a cancerous state does
require the accumulation of a series of genetic
alterations similar to those found in the in vitro
models of carcinogenesis. For instance,
hyperproliferation occurs due to the failure to
respond to growth inhibitory signals and the
functions allowing cells to divide in the absence of
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specific growth stimulatory signals. Additional
mutations must take place for cell to progress to
invasive and then metastatic states. To the extent
that each of these conditions represents a mutational
event, a clonal expansion of the cell is required for
the occurrence of mutation. Some of these changes
involve recessive events where an initial clonal
expansion of cell containing the original mutation
must be followed by a second clonal expansion with
the remaining wild type allele eliminated. If this
series of events require a greater number of cell
divisions than permitted for normal cells, potential
tumor cells must incorporate a mechanism to
overcome this limitation. It appears that in many
cases, the reactivation of telomerase serves this
purpose, yet it may not be the only mechanism. The
presence of telomerase activity only indicates that
the cell has the ability to inactivate the telomeric
“clock” that limits the proliferative capacity of normal
somatic cells[8]. The presence of telomerase activity in
a cell implies very little about malignancy, but only reflects
its potentially immortal state. Cell immortality only
gives the cells the proliferative capacity to accumulate
the necessary mutations to become malignant. As
cancer is diverse, some tumors may need only a few
mutations in order to become malignant and may not
exhaust the normal limits of proliferation before they
cause disease. These types of cancer would be expected
to be both immortal and negative for telomerase activity.
As proliferative limits can be exceeded at any time
during cancer progression, the reactivation of
telomerase would be expected to occur early in
tumors arising from cells near the limits of their
proliferative capacity and late in tumors arising from cells
with long telomeres. In some cases of tumors
arising from telomerase positive stem cells, the
initiating cells may already be competent to be
immortal.
The fact that almost all cancers have telomerase
activity, despite their shortened telomeres[2,9,10]
indicate that there is an intense selective pressure
for telomerase activation with the progression of
malignancy. Indirect support for this view comes
from the observations that benign or precancerous
lesions (e.g. colonic polyps or adenoma; prostate
hyperplasia and fibroids) are telomerase silent[9]. As
telomeres shorten, accumulated mutations in other
genes such as the genes encoding p53 and RB
(retinoblastoma protein) would result in genomic
instability, an extended life-span and progressive
erosion of telomeres[11,12]. At this point, end to end
chromosome fusions are frequently observed,
concomitantly with critically shortened telomeres.
These events could contribute to the loss of
heterozygosity and the expression of recessive
mutations, which would result in the reactivation of
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telomerase and stabilization of telomere length, as
well as fixation of the additional mutations required
for invasiveness and metastasis.
Telomerase activity in colorectal cancer

The colorectal adenoma-carcinoma sequence is one
of the best characterized models for multistep
tumorigenesis. Progression may be extremely slow
due to the high ratio of adenomas to cancers. Telomere
shortening is observed in colorectal adenomas and
carcinomas[13]. Recent studies have demonstrated
that although most adenomas lack telomerase activity,
the majority of colorectal cancers express this
enzyme [2,9] and contain detectable telomerase
activity regardless of underlying phenotype (77%
of hereditary nonpolyposis colorectal cancers;
81% of sporadic tumors, 88% with mutator
phenotypes and 75% without mutator phenotypes)[14].
Therefore, telomerase expression appears to be
commonly acquired in the progression of both
mutator phenotype and sporadic colorectal cancers.
These findings in colorectal cancer are consistent
with the telomere hypothesis. However a minority
of colorectal cancers lack detectable telomerase
activity[8] and other alternatives remain[10].
Telomerase activity in gastric cancer

The pattern of multiple gene changes in gastric
cancer varies with the histological type , well
differentiated or intestinal type and poorly
differentiated or diffuse type. However, activation
of telomerase, which is responsible for cell
immortality is the most common fundamental event
in gastrointestinal cancer[2,9,15]. Human telomerase
RNA (hTR) is expressed in pre-crisis cell lines and
non-neoplastic tissues, as well as in immortalized
cell lines or tumor specimens and the expression
level is not correlated with that of telomerase
activity[16]. Telomerase activity is detected in 85%88% of gastric carcinomatous tissues[16,17].
Although all tumor specimens and non-cancerous
mucosa expressed various levels of hTR, 81%
expressed hTR at a higher level in the tumor than
that in the corresponding mucosa. All the 8 gastric
carcinoma cell lines also expressed hTR at higher
levels. Thirty-five percent of non-cancerous mucosa
showed telomera se activity and all of them
contained intestinal metaplasia. The degree of Helicobacter pylori-infection increased in parallel
with the level of hTR expression and telomerase
positivity[17]. These results suggest that Helicobacter
pylori infection may be a strong trigger for hTR
overexpression in intest inalmetaplasia, and this
may lead to telomerase reactivation. Tumors with
telom erase activity were generally large in size with
a high frequency of lymph node metastasis. In the
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tumors without detectable telomerase activity, 80%
were early stage gastric cancer. In gastric cancer,
telomerase activation may occur as a late event of
cancer progression as demonstrated previously in
non-small cell lung cancer[18]. Moreover, the
patients with telomerase-positive tumors showed
poorer prognosis than those with telomerasenegative tumors, indicating that telomerase-positive
gastric cancers may have more malignant potential.
Telomerase activity and telomere length in
HCC and CLD

It is well known that almost all HCC are preceded
by chronic hepatitis (CH) and/or liver cirrhosis
(LC). These two conditions are regenerative lesions
in response to repeated liver damage induced by
hepatitis B or C virus (HBV/HCV) infection or
other factors. However, the role of these lesions in
HCC carcinogenesis remains unclear, except for the
possible involvement of transforming activity of the
HBVX protein[19]. There was progressive
shortening of telomeres during hepatocellular
carcinogenesis from normal liver to CH to LC to
HCC. The average telomere length of HCC was
significantly and consistently shorter than that of
adjacent CH or LC[20]. The possible role of
telomere shortening in regenerative, noncancerous
liver lesions (CH and LC) is that it may eventually
lead to reactivation of telomerase, which may then
contribute to the malignant conversion to HCC.
Thus telomere shortening in the regenerative lesions
is not merely representative of cellular aging, but
may also be a prerequisite for the development of
malignancy. A subpopulation of cells in such lesions
with telomeres shortened to a critical length, may
suffer genetic changes due to chromosome
instability[3]. These genetic changes would make
most cells senescent, but allow a small number of
cells to undergo additional mutations, including
those activating or upregulating telomerase which
then clonally develop into immortal cancer cells.
Telomere length was shorter in chronic liver diseases
compared with that in normal liver[21]. This
indicates that senescence of hepatocytes occurs in
patients with advanced liver diseases probably as a
result of degenerati on and the following
regeneration of hepatocytes. Although the
mechanisms of car cinogenesis in type C chronic liver
diseases are not known, the incidence of HCC
increases as the stage of the disease advances[22].
Telomerase activity was measured in various tissues
and cell lines[2,9,15] including HCC[23] and was
shown to be positive in 85%-100% of various
malignant tissues and negative in almost all nonmalignant tissues, except for reproductive and
haemopoietic cells. Telomerase activity was
negative in 15% of the HCC specimens[21]. One
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possible reason for this undetectability might be
false negativity due to the possible presence of
polymerase chain reaction inhibitor[24 ]. However
the presence of such inhibitor was not confirmed. In
another previous report the telomerase activity in
malignant tissue was not positive[23 ] and a recent
report has clearly shown that several tumor cell lines
keep their telomere length without telomerase
activity[25]. Consequently, some unidentified
mechanism for restoring the telomere length must
exist[26]. Thus, it seems that a small number of HCC
do not possess telomerase activity.
TELOMERASE—A TARGET FOR CANCER TREATMENT

Telomeres and telomerase play a role in signalling
cellular senescence and in the progression of
tumorigenesis, anticancer therapies could be
targeted at telomerase. The gene encoding the
human RNA component of telomerase has been
cloned[27]. Following strategies are available.
A: Obstructing telomerase RNA activity
through an antisense oligonucleotide targeted to the
template region. Encouragingly, expression of
antisense to hTR in an immortal telomeraseexpressing cell line resulted in a gradual reduction of
telomere length, leading to death of the cells[27].
B: Generation of mutant telomerase RNA.
C: Protein components of telomerase present
another viable target for inhibition.
Telomerase inhibitors may thus provide an
effective cancer therapy with no side effects of
general cancer therapy in normal somatic cells that
lack telomerase expression. A future treatment
regimen may include surgical removal of the tumor,
followed by combined antitelomerase therapy with
conventional radiation and/or chemotherapies. As
most cancer cells have much shorter telomeres than
the stem cells of renewal tissues, the treatment
period could be designed to end prior to stem cell
attrition by preserving the replicative abilities to
divide stem cells. Thus the effects of inhibiting
telomerase activity are likely to eliminate the cancer
cells long before telomere lengths in stem cells
become limited.
CONCLUSION

Clearly, telomerase regulation is complex and
further studies are needed on the multiple
mechanisms regulating telomerase activity with
respect to the addition of telomeric repeats and its
relation to cellular growth. Telomerase fulfills many
of the criteria for an ideal cancer target and has a
nearly ideal developmental and tissue-expression
pattern, what remains is to show that tumors
require telomerase for growth and that loss of
telomerase function will be clinically useful.
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